HOME 인재채용 CONTACT US KOREAN ENGLISH

과학기술안내

  1. 홈
  2. 과학기술안내

NT-I7은 독보적인 T 세포 증폭제 입니다.

인터루킨-7 (Interleukin-7, IL-7)은 T 림프구 발달과 생존에 중심적인 역할을 합니다.
인터루킨-7은 T세포 발달과 생존에 중요한 역할을 합니다1,2. T세포 숫자가 적으면, 우리 몸의 인터루킨-7이 상승하여 T세포 확장을 촉진 시킵니다. 하지만, 인터루킨-7은 항상성 사이토카인 (Homeostatic cytokine)이기 때문에, 스스로 급격히 증가하지 않아서 T세포가 부족한 상황이 매우 오랫동안 지속 됩니다3.

인터루킨-7은 CD4+ (조력 T세포)와 CD8+ (살상 T세포)에 작용하며, 나이브 T세포와 기억 T세포의 표면에 발현되는 인터루킨-7 수용체 (Interleukin-7 receptor, IL-7R)를 통해 T세포를 활성화 시킵니다. 따라서 인터루킨-7은 주요 T세포 세부종류들의 분화, 유지, 그리고 기능을 촉진 합니다. 반면에, 인터루킨-7 수용체는 조절 T세포에는 거의 발현되지 않는데, 이 T 세포종류는 T세포 반응을 제한 하는 역할을 합니다4.

네오이뮨텍은 IL-7을 기반으로 한 면역 기능향상을 위한 치료법을 연구중에 있습니다.
NT-I7은 인터루킨-7의 강화된 형태로 체내에서 더 안정적이며 T세포 증폭 효과가 오래 지속되게 합니다.
NT-I7 (efineptakin alfa)은 사람의 체내 인터루킨-7이 가진 한계들을 보완할 수 있도록 치료를 목적으로 디자인 된 융합 단백질 입니다. 인터루킨-7 도메인은 T세포 발달을 촉진시키는 핵심 도메인 인데, 구조적으로 불안정하여 N말단을 엔지니어링하여, 안정적으로 대량 제조가 가능하게 하였습니다. HyFc® 도메인은 인터루킨-7의 반감기를 연장함으로써 생체이용률 (Bioavailability)을 높여서 기존 인터루킨-7의 효능을 더 강하고 안정적이게 합니다.
인터루킨-7 도메인 HyFc® 도메인
NT-I7은 환자들의 면역기능을 향상시킬 수 있도록 T세포의 양과 기능성을 강화하여 잠재적으로 더 큰 치료 혜택을 제공할 수 있습니다.
네오이뮨텍은 면역항암, 감염증 분야에 NT-I7개발을 집중하고 있습니다. NT-I7의 암 치료 기작에 관해
자세히 알아보기 NT-I7의 감염증 치료 기작에 관해
자세히 알아보기 NT-I7의 면역질환 치료 기작에 관해
자세히 알아보기 연구 포스터 및 논문 보기
참고 문헌

1. Mazzucchelli, Renata, and Scott K. Durum. "Interleukin-7 receptor expression: intelligent design." Nature Reviews Immunology 7.2 (2007): 144-154.
2. Fry, Terry J., and Crystal L. Mackall. "Interleukin-7: from bench to clinic." Blood, The Journal of the American Society of Hematology 99.11 (2002): 3892-3904.
3. Ponchel, Frederique, et al. "Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia." Arthritis Res Ther 7.1 (2004): R80.
4. Seddiki, N. Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. "Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells." J Exp Med 203 (2006): 1693-1700.

NT-I7의 종양학 관여 기작

T세포는 암을 이겨내는데 중요한 역할을 합니다.
T세포는 암세포를 인지하고 다른 면역 세포들과 소통하여 직접 혹은 간접적으로 사멸시킵니다. T세포 증폭제로써, NT-I7은 면역 시스템을 향상시키고 종양 세포들의 효과적 박멸을 돕습니다.

네오이뮨텍은 다양한 배경의 암환자들에게 도움이 되기위해 NT-I7의 효과를 임상시험들을 통해 연구 중에 있습니다. NT-I7은 단일요법(Monotherapy)과 더불어 면역 종양학적 치료법을 포함한 여러가지 항암 치료법들과 함께 사용 될 수 있는 병용요법 (Combination therapy)들을 테스트 중에 있습니다.
NT-I7은 다양한 메커니즘으로 T세포를 통한 항종양 면역력을 증가 시킵니다.
NT-I7은 면역종양학에서 의료적으로 충족되지 못한 부분에 응답할 수 있는 독보적 자리에 있습니다.
NT-I7은 현재 면역치료법 (Immunotherapy)의 한계를 극복하기 위해 다양한 방법으로 암 면역 주기 (Cancer immunity cycle) 를 조절 합니다. 최신의 그리고 선두적인 면역 종양 치료법들과 상승적으로 작용함으로 인해 NT-I7은 더 폭 넓은 항암 효과들을 암환자에게 제공 할 수 도 있습니다.

NT-I7의 종양학 치료 기작에 관해 더 알아보려면 과학 논문 페이지 를 참조 하세요.

네오이뮨텍 (NIT)는 미국과 한국의 주요 암센터와 대학들과 협력하여 NT-I7의 임상개발을 진행중에 있습니다. 네오이뮨텍에서 진행하고 있는 암관련 임상 시험이 궁금하시면 여기 를 누르세요.

CLOSE

NT-I7의 감염증 관여 기작

NT-I7은 다양한 메커니즘으로 코로나바이러스감염증-19 (COVID-19)에 대한 면역력을 향상 시킵니다.
림프구 감소증과 후천 면역 손상은 코로나바이러스감염증-19 (COVID-19)의 환자의 사망을 포함한 다양한 임상적 예후들과 밀접한 관계가 있습니다.

인터루킨-7은 T 세포 항상성 (homeostasis)에 중요한 역할을 하며 다양한 T 세포군의 빠른 증가를 야기함과 동시에, 효과 T 세포의 탈진 (exhaustion)과 세포자연사 (apoptosis)를 억제합니다. 따라서, NT-I7은 T 세포 숫자를 증가시키며 T 세포 탈진 (exhaustion)을 억제하고 효과 T 세포의 기능을 강화시키게 되며, 이는 코로나바이러스감염증-19 환자의 임상 예후를 호전시킬 수 있습니다.

NT-I7은 여러 임상시험에서 CD4+ 와 CD8+ 나이브 T 세포와 기억 T 세포를 포함하여 절대 림프구 수치 (ALC)를 증가시킴과 동시에 임상적 내약성과 안정성을 보여주었습니다.

NT-I7은 백신 효능을 강화하는 잠재성을 가지고 있습니다.
인터루킨-7이 면역 기억 발달, 특히 T 세포 기억에 중요한 역할을 하므로 NT-I7은 항 SARS-CoV2 백신의 면역접종 효과를 향상시킬 수 있습니다. 전임상 연구에서 백신 단독투여에 비하여 NT-I7과 백신의 병용 투여가 항원 특이적 반응을 향상시키는 것으로 나타났습니다.
참고 문헌

1. Guan W, Ni Z, Hu Y et al. “Clinical Characteristics of Coronavirus Disease 2019 in China.” New England Journal of Medicine. 2020;382(18):1708-1720.
2. Huang C, Wang Y, Li X et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.” The Lancet. 2020;395(10223):497-506.
3. Tan L, Wang Q, Zhang D et al. “Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.” Signal Transduct Target Ther. 2020;5(1).
4. Terrazzini N, Mantegani P, Kern F, Fortis C, Mondino A, Caserta S. “Interleukin-7 Unveils Pathogen-Specific T Cells by Enhancing Antigen-Recall Responses.” J Infect Dis. 2018;217(12):1997-2007.
5. Deshpande P, Cavanagh M, Le Saux S, Singh K, Weyand C, Goronzy J. “IL-7– and IL-15–Mediated TCR Sensitization Enables T Cell Responses to Self-Antigens.” The Journal of Immunology. 2013;190(4):1416-1423.
6. Mackall C, Fry T, Gress R. “Harnessing the biology of IL-7 for therapeutic application.” Nature Reviews Immunology. 2011;11(5):330-342.
7. Zheng M, Gao Y, Wang G et al. “Functional exhaustion of antiviral lymphocytes in COVID-19 patients.” Cell Mol Immunol. 2020;17(5):533-535.
8. Zheng H, Zhang M, Yang C et al. “Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients.” Cell Mol Immunol. 2020;17(5):541-543.
9. Yang X, Dai T, Zhou X et al. “Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2.” 2020.

네오이뮨텍 (NIT)는 주요 암센터와 대학들과 협력하여 NT-I7의 임상개발을 진행중에 있습니다. 네오이뮨텍에서 진행하고 있는 감염증 관련 임상 시험이 궁금하시면 여기 를 누르세요.

CLOSE

NT-I7의 면역질환 치료 관여 기작

T세포는 외부 병균체의 공격을 방어하기 위한 면역 시스템 형성에 필수적인 역할을 합니다.
T세포는 특성화된 면역 세포로써 외부 병균체로 부터 우리의 몸을 방어하는데 필수적인 역할을 합니다. NT-I7은 T세포 숫자를 증가시키고 면역 기능을 재활성화 합니다.

1. 항상성의 유지

  • 가슴샘 림프구 (Thymopoiesis) 증식
  • 나이브 T 세포숫자의 증가
  • 메모리 T줄기세포를 포함한 다양한 체내 휴면 T세포의 안정적인 확보

2. 최초 면역 반응

  • 나이브 T세포의 숫자를 증가시키고 T세포 수용체의 다양성을 넓힘
  • 약한 항원에 대한 민감성을 높힘
  • T세포 수용체 (TCR) 신호기작과 상승 작용을 함

3. 적응면역계 반응

  • 메모리 T세포 분화와 회전을 촉진
  • T세포 탈진을 제한
  • 만성적 항원의 자극에도 지속적인 면역 반응을 유지

네오이뮨텍은 면역 저항력이 약한 계층을 대상으로 NT-I7의 면역 재구성과 향상에 관한 잠재적 효과를 알아보기 위한 임상 시험을 진행하고 있습니다.
  • 임상시험 번호 (NCT04054752)에서는 NT-I7의 안전성과 면역기능 재구성 및 백신에 대한 반응을 항암 약물요법 (Chemotherapy)을 받았던 노인계층
    암 생존자를 대상으로 연구하고 있습니다.
  • NT-I7은 원인이 알려져 있지 않은 CD4+ 림프구 감소증 (Idiopathic CD4+ Lymphocytopenia, ICL)의 치료용도로 희귀의약품 지정을 유럽의약청 (EMA)에서는 2017년에, 미 식품 의약청 FDA 에서는 2019년에 받았습니다. 네오이뮨텍 (NIT)는 미 과학부 (NIH) 연구자들과 ICL환자들에게 있을 수 있는 NT-I7의 잠재적 치료 효과를 알아보기 위해 임상 연구를 디자인 하고 있습니다.

NT-I7의 면역질환 치료 기작에 관해 더 알아보려면 과학 논문 페이지 를 참조 하세요.

네오이뮨텍 (NIT)는 미국과 한국의 주요 암센터와 대학들과 협력하여 NT-I7의 임상개발을 진행중에 있습니다. 네오이뮨텍에서 진행하고 있는 면역관련 임상 시험이 궁금하시면 여기 를 누르세요.

CLOSE

NT-I7의 면역질환 치료 관여 기작

T세포는 외부 병균체의 공격을 방어하기 위한 면역 시스템 형성에 필수적인 역할을 합니다.
T세포는 특성화된 면역 세포로써 외부 병균체로 부터 우리의 몸을 방어하는데 필수적인 역할을 합니다. NT-I7은 T세포 숫자를 증가시키고 면역 기능을 재활성화 합니다.

1. 항상성의 유지

  • 가슴샘 림프구 (Thymopoiesis) 증식
  • 나이브 T 세포숫자의 증가
  • 메모리 T줄기세포를 포함한 다양한 체내 휴면 T세포의 안정적인 확보

2. 최초 면역 반응

  • 나이브 T세포의 숫자를 증가시키고 T세포 수용체의 다양성을 넓힘
  • 약한 항원에 대한 민감성을 높힘
  • T세포 수용체 (TCR) 신호기작과 상승 작용을 함

3. 적응면역계 반응

  • 메모리 T세포 분화와 회전을 촉진
  • T세포 탈진을 제한
  • 만성적 항원의 자극에도 지속적인 면역 반응을 유지

네오이뮨텍은 면역 저항력이 약한 계층을 대상으로 NT-I7의 면역 재구성과 향상에 관한 잠재적 효과를 알아보기 위한 임상 시험을 진행하고 있습니다.
  • 임상시험 번호 (NCT04054752)에서는 NT-I7의 안전성과 면역기능 재구성 및 백신에 대한 반응을 항암 약물요법 (Chemotherapy)을 받았던 노인계층
    암 생존자를 대상으로 연구하고 있습니다.
  • NT-I7은 원인이 알려져 있지 않은 CD4+ 림프구 감소증 (Idiopathic CD4+ Lymphocytopenia, ICL)의 치료용도로 희귀의약품 지정을 유럽의약청 (EMA)에서는 2017년에, 미 식품 의약청 FDA 에서는 2019년에 받았습니다. 네오이뮨텍 (NIT)는 미 과학부 (NIH) 연구자들과 ICL환자들에게 있을 수 있는 NT-I7의 잠재적 치료 효과를 알아보기 위해 임상 연구를 디자인 하고 있습니다.

NT-I7의 면역질환 치료 기작에 관해 더 알아보려면 과학 논문 페이지 를 참조 하세요.

네오이뮨텍 (NIT)는 미국과 한국의 주요 암센터와 대학들과 협력하여 NT-I7의 임상개발을 진행중에 있습니다. 네오이뮨텍에서 진행하고 있는 면역관련 임상 시험이 궁금하시면 여기 를 누르세요.

CLOSE

연구 포스터 및 논문

NT-I7 임상 연구 (Clinical Research) 포스터 및 학회 발표
  1. Kim R, Mamdani H, Brave M, "Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-Naïve Advanced MSS-Colorectal Cancer" Poster Presented at ESMO-GI; Jul. 1st, 2022; Barcelona, Spain. (Click Here )
  2. Naing A, Mamdani H, Brave M, "Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-Naïve Advanced Pancreatic Cancer" Poster Presented at ESMO-GI; Jun. 30th, 2022; Barcelona, Spain. (Click Here )
  3. Gastman B, Fling S, Ansstas G, "A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report." Poster Presented at ASCO; Jun. 6th, 2022; Chicago, IL. (Click Here )
  4. Naing A, Mamdani H, Brave M, "Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study." Poster Presented at ASCO; Jun. 5th, 2022; Chicago, IL. (Click Here ) **Selected for poster discussion session
  5. Ghobadi A, Budde L, Galal A, "Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma" Poster Presented (Click Here )
  6. Sohn J, Kim G, Lee K, “Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.” Poster Presented at ASCO; Jun. 1st, 2022; Chicago, IL.* (Click Here )
  7. Campian Jian Li, et al. “A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy” Oral Presentation Presented at SNO; Nov 19th, 2021; Boston, MA. (Click Here )
  8. Zhou A, Rettig M, Foltz Jennifer. “NT-I7,a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  9. Naing A, Kim R, Barve M. “Preliminary biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  10. Kim R, Barve M, Mamdani H, “Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  11. Campian Jian Li, et al. “A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data.” Poster Presented at ASCO; May. 28th, 2021; Virtual Presentation. (Click Here )
  12. Naing A, Fan J, Lee B, “Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report.” Poster Presented at ASCO; May. 28th, 2021; Virtual Presentation. (Click Here )
  13. Sohn J, Im Y, “Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study.” Poster Presented at SITC; Oct. 10th, 2020; Virtual Presentation.* (Click Here )
  14. Sohn J, Park K, Ahn H, “Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).” Poster Presented at ASCO; May. 25th, 2020; Virtual Presentation.* (Click Here )
  15. Lee S, Choi D, Heo M, “Hyleukin-7, a long-acting interleukin-7, increased absolute lymphocyte counts after subcutaneous and intramuscular administration in healthy subjects.” Poster Presented at AACR; Mar. 30th, 2019; Atlanta, GA.* (Click Here )
  16. Heo M, Sohn J, Lee M, “Phase 1b study of GX-I7, a long-acting interleukin-7, evaluating the safety, pharmacokinetics and pharmacodynamics profiles in patients with advanced solid cancers.” Poster Presented at SITC; Nov. 6th, 2019; National Harbor, MD.* (Click Here )
NT-I7 전 임상 실험과 중개 연구 (Preclinical and Translational Research) 포스터 및 학회 발표
  1. Baek S, Im SK, Lee M, "rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with anti-TIGIT or anti-VEGF" Poster Presented at AACR; Apr. 13th, 2022; New Orleans, LA. (Click Here )
  2. Baek S, Im SK, Lee M, "rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex" Poster Presented at AACR; Apr. 13th, 2022; New Orleans, LA. (Click Here )
  3. Bardahl J, Jiao Y, Wolfarth A, “Effects of a novel long-acting IL-7 on T cell reconstitution following allogeneic hematopoietic cell transplantation” Poster Presented at Duke Pediatrics Research Retreat; Apr. 28th, 2022; Durham, NC. (Click Here )
  4. Niavi C, Lee J, McManus D, “Effect of NT-I7 treatment on CD8 T cell differentiation during chronic LCMV” Poster Presented at SIS 2022; Jun. 11th, 2022; Durham, NC. (Click Here )
  5. Liang T, Li, D, Ferrando-Martinez S, “Influence of NT-I7, an engineered long-acting interleukin-7, on CAR T cell therapy in liver cancer” Poster Presented at PEGS 2022; May 4th, 2022, Boston, MA. (Click Here )
  6. Campian, Jian Li, et al. ”A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8 cells and enhances survival in mouse glioma models.” Oral Presentation Presented at SNO 2020; Virtual Presentation. (Click Here )
  7. Park S, Kim J, Kang Y, “Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice” Poster Presented at SITC; Nov. 09th 2020; Virtual Presentation. (Click Here )
  8. Ghosh S, Yan R, Thotala S, “A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models” Poster Presented at SITC; Dec. 10th 2020; Virtual Presentation. (Click Here )
  9. O'Neal, Julie, et al. "In vivo efficacy of BCMA-iNKT-CAR is enhanced by NT-I7, a long-acting IL-7.” Oral Presentation Presented at 17th International Myeloma Workshop; Sep. 13th, 2019; Boston, MA. (Click Here )
  10. Campian, Jian Li, et al. "Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma.” Abstract submitted for ASCO; May. 31st, 2019: e13516. (Click Here )
  11. Kim J, Hong S, Kim Y, "Hyleukin-7, the Fc-fused interleukin-7, generates anti-tumor activity by modulating both adaptive and innate immune cells in the tumor microenvironment.” Poster Presented at AACR; Mar. 30th, 2019; Atlanta, GA. * (Click Here )
  12. Cooper ML, Staser KW, Niswonge J, "A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates CART Proliferation, Differentiation, and Tumor Killing.” Poster Presented at TCT-Transplant & Cellular Therapy: Feb. 20th, 2019; Houston, TX. (Click Here )
  13. Staser KW, Cooper ML, Choi J, "Modeling Sezary Syndrome For Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy.” Poster Presented at TCT-Transplant & Cellule Therapy: Feb. 20th, 2019; Houston, TX. (Click Here )
  14. Staser KW, Cooper ML, Choi J, "Modeling Sezary Syndrome For Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy.” Poster Presented at ASH Annual Meeting; Dec. 2nd, 2018; San Diego, CA. (Click Here )
  15. Cooper M, Staser K, Davenport J, "A long-acting pharmacological grade interleukin-7 molecule logarithmically accelerates UCAR-T proliferation, differentiation, and tumor killing.” Oral Presentation Presented at ASH Annual Meeting; Dec. 2nd, 2018; San Diego, CA. (Click Here )
  16. Kim J, Choi D, Ji M, "Preclinical evaluation of the anti-tumor activity of Fc-fused interleukin-7 in both monotherapy and combination therapy.” Poster Presented at AACR; Apr. 14th, 2018; Chicago, IL. (Click Here )
연구 논문
  1. Kim, Miriam Y. et al. "A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity" Nature Communications (2022).    https://doi.org/10.1038/s41467-022-30860-0
  2. Wolfarth, Alexandra A. et al. “Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy” Immune Network (2022).   https://doi.org/10.4110/in.2022.22.e5
  3. Campian, Jian L. et al. “Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 + T cells and enhances survival in mouse glioma models” Clinical Cancer Research (2022).   https://doi.org/10.1158/1078-0432.CCR-21-0947
  4. Kim, Miriam Y, et al. “CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy” JCI Insight (2021).   https://doi.org/10.1172/jci.insight.149819
  5. Kim, Ji-Hae, et al. “Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7.” BMB Reports (2021).   https://doi.org/10.5483/BMBRep.2021.54.1.257
  6. Foluso O Ademuyiwa, et al. “Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.” Breast Cancer Research and Treatment (2021).   https://doi.org/10.1007/s10549-021-06307-3
  7. Kim, Sora, et al. “Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100.” Leukemia(2021).   https://doi.org/10.1038/s41375-021-01274-6
  8. Kim, Ji-Hae, et al. “Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.” Clinical and Translational Immunology (2020).   https://doi.org/10.1002/cti2.1168
  9. Lee, Sang Won, et al. "hIL-7-hyFc, a long-acting IL-7, increased absolute lymphocyte count in healthy subjects.” Clinical and Translational Science (2020). [Epub ahead of print]   https://doi.org/10.1111/cts.12800
  10. Choi, Young Woo, et al. "Intravaginal administration of Fc-fused IL7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells." Clinical Cancer Research 22.23 (2016): 5898-5908.   https://doi.org/10.1158/1078-0432.CCR-16-0423
  11. Lim, Jun Yeul, et al. "Biophysical stability of hyFc fusion protein with regards to buffers and various excipients." International journal of biological macromolecules 86 (2016): 622-629.   https://doi.org/10.1016/j.ijbiomac.2016.02.006
  12. Kang, Moon Cheol, et al. "Intranasal introduction of Fc-fused interleukin-7 provides long-lasting prophylaxis against lethal influenza virus infection." Journal of virology 90.5 (2016): 2273-2284.   https://doi.org/10.1128/jvi.02768-15
  13. Seo, Yong Bok, et al. "Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity." Journal of virology 88.16 (2014): 8998-9009.   https://doi.org/10.1128/JVI.00534-14
  14. Ahn, So-Shin, et al. "Nonlytic Fc-fused NT-I7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis." Vaccine 31.27 (2013): 2884-2890.   https://doi.org/10.1016/j.vaccine.2013.04.029
  15. Nam, Hyo Jung, et al. "Marked enhancement of antigen‐specific T‐cell responses by IL‐7‐fused nonlytic, but not lytic, Fc as a genetic adjuvant." European journal of immunology 40.2 (2010): 351-358.   https://doi.org/10.1002/eji.200939271
* Posters presented by Genexine, Inc.
CLOSE

연구 포스터 및 논문

NT-I7 임상 연구 (Clinical Research) 포스터 및 학회 발표
  1. Naing A, Ferrando-Martinez S, Ware M, "NT-I7, a long-acting IL-7, plus pembrolizumab favors CD8 T-cell infiltration in liver metastases of heavily pre-treated, immunologically cold, MSS-colorectal and pancreatic cancer" Oral Presentation Presented at SITC; Nov 11, 2022; Boston, MA. (Click Here )
  2. Butt O, Tao Y, Huang J, "A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy" Poster Presented at SITC; Nov 11, 2022; Boston, MA. (Click Here )
  3. Kang H, Spitzer M, Kim MO, "NT-I7 for the treatment of locally recurrent squamous cell carcinoma of head and neck undergoing salvage surgery: a clinical trial in progress" Poster Presented at SITC; Nov 10, 2022; Boston, MA (Click Here )
  4. Naing A, Ferrando-Martinez S, Wolfarth A, "NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment: Biomarker data from the NIT-110 study" Poster Presented at ESMO; Sep. 1st, 2022; Paris, France. (Click Here )
  5. Kim R, Mamdani H, Brave M, "Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-Naïve Advanced MSS-Colorectal Cancer" Poster Presented at ESMO-GI; Jul. 1st, 2022; Barcelona, Spain. (Click Here )
  6. Naing A, Mamdani H, Brave M, "Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-Naïve Advanced Pancreatic Cancer" Poster Presented at ESMO-GI; Jun. 30th, 2022; Barcelona, Spain. (Click Here )
  7. Gastman B, Fling S, Ansstas G, "A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report." Poster Presented at ASCO; Jun. 6th, 2022; Chicago, IL. (Click Here )
  8. Naing A, Mamdani H, Brave M, "Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study." Poster Presented at ASCO; Jun. 5th, 2022; Chicago, IL. (Click Here ) **Selected for poster discussion session
  9. Ghobadi A, Budde L, Galal A, "Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma" Poster Presented at ASCO; Jun. 4th, 2022; Chicago, IL. (Click Here )
  10. Sohn J, Kim G, Lee K, “Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.” Poster Presented at ASCO; Jun. 1st, 2022; Chicago, IL.* (Click Here )
  11. Campian Jian Li, et al. “A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy” Oral Presentation Presented at SNO; Nov 19th, 2021; Boston, MA. (Click Here )
  12. Zhou A, Rettig M, Foltz Jennifer. “NT-I7,a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  13. Naing A, Kim R, Barve M. “Preliminary biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  14. Kim R, Barve M, Mamdani H, “Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer” Poster Presented at SITC; Sep. 13th, 2021; Washington, D.C. (Click Here )
  15. Campian Jian Li, et al. “A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data.” Poster Presented at ASCO; May. 28th, 2021; Virtual Presentation. (Click Here )
  16. Naing A, Fan J, Lee B, “Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report.” Poster Presented at ASCO; May. 28th, 2021; Virtual Presentation. (Click Here )
  17. Sohn J, Im Y, “Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study.” Poster Presented at SITC; Oct. 10th, 2020; Virtual Presentation.* (Click Here )
  18. Sohn J, Park K, Ahn H, “Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).” Poster Presented at ASCO; May. 25th, 2020; Virtual Presentation.* (Click Here )
  19. Lee S, Choi D, Heo M, “Hyleukin-7, a long-acting interleukin-7, increased absolute lymphocyte counts after subcutaneous and intramuscular administration in healthy subjects.” Poster Presented at AACR; Mar. 30th, 2019; Atlanta, GA.* (Click Here )
  20. Heo M, Sohn J, Lee M, “Phase 1b study of GX-I7, a long-acting interleukin-7, evaluating the safety, pharmacokinetics and pharmacodynamics profiles in patients with advanced solid cancers.” Poster Presented at SITC; Nov. 6th, 2019; National Harbor, MD.* (Click Here )
NT-I7 전 임상 실험과 중개 연구 (Preclinical and Translational Research) 포스터 및 학회 발표
  1. Phoon Y, Kai K, Wolfarth A, "NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model" Poster Presented at SITC; Nov 10, 2022; Boston, MA. (Click Here )
  2. Lee KJ, Tae N, Kang YW, "Redirecting IL-7-induced bystander tumor-infiltrating lymphocytes by bispecific T cell engager augments antitumor response" Poster Presented at SITC; Nov 10, 2022; Boston, MA. (Click Here )
  3. Zou Y, Jiao Y, Wolfarth A, "NT-I7, a long-acting recombinant human interleukin-7, enhances T cell reconstitution following total body irradiation" Poster Presented at RRS; Oct 17, 2022; Waikoloa Village, HI. (Click Here )
  4. Zou Y, Jiao Y, Wolfarth A, "NT-I7, a long-acting recombinant human interleukin-7, enhances T cell reconstitution following total body irradiation" Oral Presentation Presented at RITN; Aug 4, 2022; Alexandria, VA. (Click Here )
  5. Baek S, Im SK, Lee M, "rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with anti-TIGIT or anti-VEGF" Poster Presented at AACR; Apr. 13th, 2022; New Orleans, LA. (Click Here )
  6. Baek S, Im SK, Lee M, "rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex" Poster Presented at AACR; Apr. 13th, 2022; New Orleans, LA. (Click Here )
  7. Bardahl J, Jiao Y, Wolfarth A, “Effects of a novel long-acting IL-7 on T cell reconstitution following allogeneic hematopoietic cell transplantation” Poster Presented at Duke Pediatrics Research Retreat; Apr. 28th, 2022; Durham, NC. (Click Here )
  8. Niavi C, Lee J, McManus D, “Effect of NT-I7 treatment on CD8 T cell differentiation during chronic LCMV” Poster Presented at SIS 2022; Jun. 11th, 2022; Durham, NC. (Click Here )
  9. Liang T, Li, D, Ferrando-Martinez S, “Influence of NT-I7, an engineered long-acting interleukin-7, on CAR T cell therapy in liver cancer” Poster Presented at PEGS 2022; May 4th, 2022, Boston, MA. (Click Here )
  10. Campian, Jian Li, et al. ”A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8 cells and enhances survival in mouse glioma models.” Oral Presentation Presented at SNO 2020; Virtual Presentation. (Click Here )
  11. Park S, Kim J, Kang Y, “Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice” Poster Presented at SITC; Nov. 09th 2020; Virtual Presentation. (Click Here )
  12. Ghosh S, Yan R, Thotala S, “A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models” Poster Presented at SITC; Dec. 10th 2020; Virtual Presentation. (Click Here )
  13. O'Neal, Julie, et al. "In vivo efficacy of BCMA-iNKT-CAR is enhanced by NT-I7, a long-acting IL-7.” Oral Presentation Presented at 17th International Myeloma Workshop; Sep. 13th, 2019; Boston, MA. (Click Here )
  14. Campian, Jian Li, et al. "Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma.” Abstract submitted for ASCO; May. 31st, 2019: e13516. (Click Here )
  15. Kim J, Hong S, Kim Y, "Hyleukin-7, the Fc-fused interleukin-7, generates anti-tumor activity by modulating both adaptive and innate immune cells in the tumor microenvironment.” Poster Presented at AACR; Mar. 30th, 2019; Atlanta, GA. * (Click Here )
  16. Cooper ML, Staser KW, Niswonge J, "A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates CART Proliferation, Differentiation, and Tumor Killing.” Poster Presented at TCT-Transplant & Cellular Therapy: Feb. 20th, 2019; Houston, TX. (Click Here )
  17. Staser KW, Cooper ML, Choi J, "Modeling Sezary Syndrome For Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy.” Poster Presented at TCT-Transplant & Cellule Therapy: Feb. 20th, 2019; Houston, TX. (Click Here )
  18. Staser KW, Cooper ML, Choi J, "Modeling Sezary Syndrome For Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy.” Poster Presented at ASH Annual Meeting; Dec. 2nd, 2018; San Diego, CA. (Click Here )
  19. Cooper M, Staser K, Davenport J, "A long-acting pharmacological grade interleukin-7 molecule logarithmically accelerates UCAR-T proliferation, differentiation, and tumor killing.” Oral Presentation Presented at ASH Annual Meeting; Dec. 2nd, 2018; San Diego, CA. (Click Here )
  20. Kim J, Choi D, Ji M, "Preclinical evaluation of the anti-tumor activity of Fc-fused interleukin-7 in both monotherapy and combination therapy.” Poster Presented at AACR; Apr. 14th, 2018; Chicago, IL. (Click Here )
연구 논문
  1. Ware, Michael B. et al. "The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers" Journal of Immunotherapy and Precision Oncology 5.4 (2022): 105-117.    https://doi.org/10.36401/JIPO-22-10
  2. Kim, Sojeong et al. "A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained functions and TCR diversity" Blood Advances (2022).    https://doi.org/10.1182/bloodadvances.2021006591
  3. Kim, Miriam Y. et al. "A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity" Nature Communications (2022).    https://doi.org/10.1038/s41467-022-30860-0
  4. Wolfarth, Alexandra A. et al. “Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy” Immune Network (2022).   https://doi.org/10.4110/in.2022.22.e5
  5. Campian, Jian L. et al. “Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 + T cells and enhances survival in mouse glioma models” Clinical Cancer Research (2022).   https://doi.org/10.1158/1078-0432.CCR-21-0947
  6. Kim, Miriam Y, et al. “CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy” JCI Insight (2021).   https://doi.org/10.1172/jci.insight.149819
  7. Kim, Ji-Hae, et al. “Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7.” BMB Reports (2021).   https://doi.org/10.5483/BMBRep.2021.54.1.257
  8. Foluso O Ademuyiwa, et al. “Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.” Breast Cancer Research and Treatment (2021).   https://doi.org/10.1007/s10549-021-06307-3
  9. Kim, Sora, et al. “Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100.” Leukemia(2021).   https://doi.org/10.1038/s41375-021-01274-6
  10. Kim, Ji-Hae, et al. “Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.” Clinical and Translational Immunology (2020).   https://doi.org/10.1002/cti2.1168
  11. Lee, Sang Won, et al. "hIL-7-hyFc, a long-acting IL-7, increased absolute lymphocyte count in healthy subjects.” Clinical and Translational Science (2020). [Epub ahead of print]   https://doi.org/10.1111/cts.12800
  12. Choi, Young Woo, et al. "Intravaginal administration of Fc-fused IL7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells." Clinical Cancer Research 22.23 (2016): 5898-5908.   https://doi.org/10.1158/1078-0432.CCR-16-0423
  13. Lim, Jun Yeul, et al. "Biophysical stability of hyFc fusion protein with regards to buffers and various excipients." International journal of biological macromolecules 86 (2016): 622-629.   https://doi.org/10.1016/j.ijbiomac.2016.02.006
  14. Kang, Moon Cheol, et al. "Intranasal introduction of Fc-fused interleukin-7 provides long-lasting prophylaxis against lethal influenza virus infection." Journal of virology 90.5 (2016): 2273-2284.   https://doi.org/10.1128/jvi.02768-15
  15. Seo, Yong Bok, et al. "Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity." Journal of virology 88.16 (2014): 8998-9009.   https://doi.org/10.1128/JVI.00534-14
  16. Ahn, So-Shin, et al. "Nonlytic Fc-fused NT-I7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis." Vaccine 31.27 (2013): 2884-2890.   https://doi.org/10.1016/j.vaccine.2013.04.029
  17. Nam, Hyo Jung, et al. "Marked enhancement of antigen‐specific T‐cell responses by IL‐7‐fused nonlytic, but not lytic, Fc as a genetic adjuvant." European journal of immunology 40.2 (2010): 351-358.   https://doi.org/10.1002/eji.200939271
* Posters presented by Genexine, Inc.
CLOSE